SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

JAGSONPAL PHARMACEUTICALS

BSE: 507789 28 Jun 2025
Healthcare
₹ 217.15
Jagsonpal Pharmaceuticals Limited, specializes in Pharmaceuticals within the Healthcare sector.

JAGSONPAL PHARMACEUTICALS - Share Price & Details

Market Cap
₹1,423
High /Low
328.0 / 126.0
Stock P/E
35.8
Book Value
₹36.1
Dividend Yield
0.93
ROCE
23.0
ROE
₹18.6
Face Value
2.0
PEG Ratio
0.94
EVEBITDA
₹22.0
Debt
9.24
CMP / FCF
24.7
Debt to equity
₹0.04
NP Ann
55.4
High price all time
328.0
Piotroski score
₹6.0
Graham Number
82.4
No. Eq. Shares
6.65
Net CF
₹-1.55
Net profit
55.4
Price to book value
5.92
Interest Coverage
₹53.3
Low price all time
2.4
Industry PE
32.0
Reserves
₹227
Free Cash Flow
₹90.7

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
LOOKS HEALTH SERVICES LIMITEDNANANANA5.11256.0
Triochem Products Ltd.,NANANANA0
JAGSONPAL PHARMACEUTICALS LTD.613.365.83585.60.981,42335.8
THEMIS MEDICARE LTD.732.53-77.45717.02-0.84119340.0
LINCOLN PHARMACEUTICALS LTD.1613.03115.751681.835.78113113.7

Peer Comparison Chart


About JAGSONPAL PHARMACEUTICALS

Jagsonpal Pharmaceuticals Limited,, with Security Code 507789, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Has Jagsonpal Pharma declared dividend?

(07 Jun 2025)
Jagsonpal Pharmaceuticals Ltd has declared a 100% dividend, amounting to ₹5 per share, with an ex-date of September 6, 2024. The company has shown strong...
Read more →

Jagsonpal Pharmaceuticals Shows Mixed Technical Trends Amid Strong Long-Term Performance

(02 Jun 2025)
Jagsonpal Pharmaceuticals, a small-cap firm in the Pharmaceuticals and Biotechnology sector, has seen its stock price decline recently.
Read more →

We Think That There Are Issues Underlying Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

(14 May 2025)
Investors were disappointed with Jagsonpal Pharmaceuticals Limited's ( NSE:JAGSNPHARM ) earnings, despite the strong...
Read more →

Jagsonpal Pharmaceuticals posts Q4 FY25 PAT at Rs. 6.58 Cr

(14 May 2025)
Jagsonpal Pharmaceuticals Ltd has reported Standalone financial results for the period ended March 31, 2025. Jagsonpal Pharmaceuticals has...
Read more →

Jagsonpal Pharmaceuticals Full Year 2025 Earnings: EPS: ₹8.26 (vs ₹3.40 in FY 2024)

(13 May 2025)
Jagsonpal Pharmaceuticals ( NSE:JAGSNPHARM ) Full Year 2025 Results Key Financial Results Revenue: ₹2.77b (up 33% from...
Read more →

Jagsonpal Pharmaceuticals Sees Trend Reversal Amid Broader Market Surge

(12 May 2025)
Jagsonpal Pharmaceuticals experienced a notable stock performance on May 12, 2025, reversing a four-day decline with a significant intraday...
Read more →